Mankind Pharma Ltd Stock Price Today (NSE: MANKIND)
Fundamental Score
Mankind Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Mankind Pharma Ltd share price today is ₹2492.60, down 0.12% on NSE/BSE as of 22 May 2026. Mankind Pharma Ltd (MANKIND) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹92.01K (Cr). The 52-week high for MANKIND share price is ₹2716.50 and the 52-week low is ₹1909.70. At a P/E ratio of 52.62x, MANKIND is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 14.68% and a debt-to-equity ratio of 0.55.
Mankind Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Mankind Pharma Ltd share price chart: 16.26% return over the past month. 52-week high ₹2716.50, 52-week low ₹1909.70.
Mankind Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2504.00 | ₹2549.90 | ₹2470.00 | ₹2492.60 | 5.74L (Cr) | |
| ₹2507.10 | ₹2513.00 | ₹2467.00 | ₹2495.70 | 3.14L (Cr) | |
| ₹2477.00 | ₹2534.90 | ₹2449.30 | ₹2503.00 | 11.21L (Cr) | |
| ₹2417.00 | ₹2474.50 | ₹2417.00 | ₹2462.20 | 4.98L (Cr) | |
| ₹2362.00 | ₹2455.90 | ₹2352.10 | ₹2407.60 | 5.95L (Cr) | |
| ₹2470.00 | ₹2470.00 | ₹2353.60 | ₹2378.90 | 5.54L (Cr) | |
| ₹2423.10 | ₹2510.00 | ₹2400.00 | ₹2468.80 | 6.72L (Cr) | |
| ₹2377.80 | ₹2464.90 | ₹2377.80 | ₹2430.80 | 10.79L (Cr) | |
| ₹2379.50 | ₹2385.00 | ₹2345.50 | ₹2375.20 | 6.67L (Cr) | |
| ₹2334.50 | ₹2370.00 | ₹2292.30 | ₹2361.00 | 8.55L (Cr) |
Mankind Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2249.20 | ₹2549.90 | ₹2239.60 | ₹2492.60 | +10.82% | |
| ₹2016.00 | ₹2322.20 | ₹1928.00 | ₹2246.70 | +11.44% | |
| ₹2161.00 | ₹2256.80 | ₹1909.70 | ₹2005.80 | -7.18% | |
| ₹2100.00 | ₹2284.90 | ₹2012.30 | ₹2247.60 | +7.03% | |
| ₹2202.00 | ₹2320.90 | ₹2059.40 | ₹2124.00 | -3.54% | |
| ₹2260.00 | ₹2260.00 | ₹2090.00 | ₹2196.50 | -2.81% | |
| ₹2383.30 | ₹2408.60 | ₹2198.50 | ₹2251.00 | -5.55% | |
| ₹2420.00 | ₹2511.90 | ₹2368.00 | ₹2384.00 | -1.49% | |
| ₹2473.50 | ₹2674.00 | ₹2425.00 | ₹2435.70 | -1.53% | |
| ₹2569.70 | ₹2661.50 | ₹2410.00 | ₹2471.40 | -3.83% | |
| ₹2335.00 | ₹2716.50 | ₹2258.00 | ₹2567.20 | +9.94% | |
| ₹2466.00 | ₹2471.90 | ₹2279.40 | ₹2319.80 | -5.93% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Mankind Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Mankind Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MANKIND across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (15.98%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (24.52%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (20.77%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (15.79% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Cash Generation (₹4055.69 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (72.67%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 52.62x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-22.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Mankind Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Mankind Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Mankind Pharma LtdMankind Pharma ...Selected✓ MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6912.00₹6912 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1409.80₹1410 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1512.80₹1513 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5470.00₹5470 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Abbott India LtdAbbott India Lt... ABBOTINDIA • 500488 | 65/100 | ₹27795.00₹27795 | ₹63358.16₹63358.16 | 41.99Average 42.0 Average | 35.68%Excellent 35.68% Excellent | 46.25%Excellent 46.25% Excellent | 0.05Excellent 0.1 Excellent | 18.98%Excellent 18.98% Excellent | 9.38%Good 9.38% Good | 1.59% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Mankind Pharma Ltd PE Ratio History
Historical price-to-earnings ratio for MANKIND — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹49.20 | ₹2196.50 | 44.6x |
| FY 2024 | ₹47.68 | ₹2880.40 | 60.4x |
| FY 2023 | ₹32.00 | ₹1982.50 | 62x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Mankind Pharma Ltd Quarterly Performance
Latest quarterly metrics for MANKIND — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
20.77%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-22.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
15.79%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
11.73%
Compounded annual net profit growth over 5 years
Mankind Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for MANKIND — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Mankind Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Mankind Pharma Ltd (MANKIND) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Mankind Pharma Ltd
About MANKIND (Mankind Pharma Ltd)
Mankind Pharma Ltd is a prominent pharmaceutical company committed to enhancing healthcare accessibility across India and beyond. With a robust foundation built on innovation and a...ffordability, the company formulates, produces, and commercializes a diverse portfolio of pharmaceutical products and consumer healthcare solutions. Mankind Pharma distinguishes itself by addressing critical therapeutic needs in both acute and chronic disease management. Its pharmaceutical offerings encompass a wide range of therapeutic areas, including treatments for infections, cardiovascular conditions, gastrointestinal disorders, gynecological issues, diabetes, dermatological ailments, pain management, neurological conditions, and respiratory illnesses. Through its dedication to providing high-quality medicines at affordable prices, Mankind Pharma has established a strong presence in the Indian pharmaceutical market. Beyond its pharmaceutical endeavors, Mankind Pharma also caters to consumer healthcare needs with a range of well-known products. This segment includes well-known items aimed at promoting overall wellness and reproductive health. These consumer healthcare products complement the company's pharmaceutical offerings, reinforcing its commitment to comprehensive healthcare solutions. The company aims to empower individuals to take proactive control of their health, contributing to improved well-being and a better quality of life. Through these products, Mankind Pharma reinforces its mission of providing reliable and accessible healthcare options for all, further solidifying its position as a trusted healthcare provider. Mankind Pharma remains dedicated to expanding its research and development capabilities to introduce innovative and effective healthcare solutions. By focusing on continuous improvement and strategic collaborations, the company is well-positioned to meet the evolving needs of patients and healthcare professionals. With a strong commitment to quality, affordability, and accessibility, Mankind Pharma continues to play a vital role in the pharmaceutical landscape, both domestically and internationally. Its dedication to providing accessible and effective healthcare options has positioned Mankind Pharma as a significant contributor to the well-being of individuals and communities across India and beyond.
Company Details
Key Leadership
Corporate Events
Latest News
MANKIND Share Price: Frequently Asked Questions
What is the current share price of Mankind Pharma Ltd?
Mankind Pharma Ltd (MANKIND) trades at ₹2492.60 on NSE and BSE. Market cap ₹92.01K (Cr). Educational data only.
What is the P/E ratio of Mankind Pharma Ltd?
Mankind Pharma Ltd has a P/E of 52.62x vs industry average 31.77x.
What is the Bull Run score for Mankind Pharma Ltd?
Mankind Pharma Ltd has a Bull Run score of 50.6/100 based on 25+ financial parameters.
Does Mankind Pharma Ltd pay dividends?
Mankind Pharma Ltd has a dividend yield of 0.04%. Past dividends don't guarantee future payments.
What is the ROE of Mankind Pharma Ltd?
Mankind Pharma Ltd has ROE of 14.68%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Mankind Pharma Ltd?
Mankind Pharma Ltd has debt-to-equity of 0.55.
Is Mankind Pharma Ltd a good investment?
Bull Run gives Mankind Pharma Ltd a score of 50.6/100. This is not investment advice — consult a SEBI-registered advisor.